Format

Send to

Choose Destination
Nat Med. 2013 Aug;19(8):998-1004. doi: 10.1038/nm.3267. Epub 2013 Aug 6.

Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies.

Lee AS#1,2,3, Tang C#1,4, Rao MS5, Weissman IL1, Wu JC1,2,3.

Author information

1
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California 94305, USA.
2
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California 94305, USA.
3
Department of Medicine, Division of Cardiology Stanford University School of Medicine, Stanford, California 94305, USA.
4
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
5
National Center for Regenerative Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA.
#
Contributed equally

Abstract

Human pluripotent stem cells (PSCs) are a leading candidate for cell-based therapies because of their capacity for unlimited self renewal and pluripotent differentiation. These advances have recently culminated in the first-in-human PSC clinical trials by Geron, Advanced Cell Technology and the Kobe Center for Developmental Biology for the treatment of spinal cord injury and macular degeneration. Despite their therapeutic promise, a crucial hurdle for the clinical implementation of human PSCs is their potential to form tumors in vivo. In this Perspective, we present an overview of the mechanisms underlying the tumorigenic risk of human PSC-based therapies and discuss current advances in addressing these challenges.

PMID:
23921754
PMCID:
PMC3967018
DOI:
10.1038/nm.3267
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center